Telomir Pharmaceuticals, Inc. announced the commencement of several significant milestones. These events underscore its commitment to advancing innovative treatments to mitigate the effects of aging and the continuation of its work. Initiation of The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days Study: On May 28, 2024, Telomir began a pivotal study analyzing telomere length to evaluate the aging process and safety of Telomir-1, in geriatric canines, beginning with four canines receiving active doses and one canine receiving placebo doses.

Telomir-1 is the Company?s therapeutic candidate aimed at addressing age-related diseases in humans and animals. The company believe this study represents a crucial step in the Company?s efforts to develop effective treatments for chronic conditions, which affects millions of pets and humans alike. Dosing of Zeus, A Geriatric German Shepherd: In parallel with the pivotal canine study, the Company also announced that it is currently using Telomir-1 to treat Zeus, a 12-year-old German Shepherd.

Zeus has completed over a month of daily dosing. This case will provide valuable insights and real-world data that will inform its ongoing and future research and regulatory initiatives which target age-related diseases, oncology and post-surgery recovery.